Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MmDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMEC2Olkh|ryP NH;TbmhUSU6JRWK=
MV-4-11 M33LTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17Z[WlEPTB;MD6wNVU5PiEQvF2= NH;HNVNUSU6JRWK=
NKM-1 MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP2TWM2OD1yLkCxOlk6KM7:TR?= M1u4VHNCVkeHUh?=
ML-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMEG5PFMh|ryP NVOxOW9DW0GQR1XS
BV-173 NF;Gc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMEKzNVQh|ryP NETEXnVUSU6JRWK=
RS4-11 MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMEK1PFch|ryP M2joXnNCVkeHUh?=
HL-60 M3PSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\TPJVKSzVyPUCuNFI6ODhizszN NEe4ToxUSU6JRWK=
KY821 NHzYO|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjRTWM2OD1yLkCyPVc2KM7:TR?= NXj6RWxFW0GQR1XS
ECC10 MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;UTWM2OD1yLkCzO|kzKM7:TR?= M{DWWHNCVkeHUh?=
NCI-H720 MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLxflVKSzVyPUCuNFQxOTFizszN MmX2V2FPT0WU
QIMR-WIL M2P5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\pcHo3UUN3ME2wMlA1Ojh5IN88US=> MlTLV2FPT0WU
KG-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2S0T2lEPTB;MD6wOFQ5PiEQvF2= MojlV2FPT0WU
TGW NG\NRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H5WWlEPTB;MD6wOFY{OyEQvF2= M{\wO3NCVkeHUh?=
ATN-1 NFfzdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j4NmlEPTB;MD6wOFc{OyEQvF2= M2[4dXNCVkeHUh?=
RH-18 NWThOpZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfJTIVKSzVyPUCuNFYxPDhizszN M4jDW3NCVkeHUh?=
EW-18 NU\ibFFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwME[4OFEh|ryP MlTvV2FPT0WU
NB17 M1zvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O5RWlEPTB;MD6wO|EzPCEQvF2= M3PUN3NCVkeHUh?=
SK-NEP-1 Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMEeyNVMh|ryP NYfoTZA5W0GQR1XS
P12-ICHIKAWA NYTDbGdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jwdGlEPTB;MD6wO|c4QCEQvF2= NWLUclNsW0GQR1XS
KARPAS-45 Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHLTWM2OD1yLkC3PFE2KM7:TR?= MnH3V2FPT0WU
EW-3 MlvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[3[WlEPTB;MD6wPFA2OyEQvF2= NFiydYNUSU6JRWK=
NB13 MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LFcmlEPTB;MD6wPFIxOyEQvF2= M3\TcnNCVkeHUh?=
NCI-H209 NXXlSZhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHGycmFKSzVyPUCuNFg4ODRizszN M1frTXNCVkeHUh?=
NCI-H1092 M1[xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmS2TWM2OD1yLkGwNlc2KM7:TR?= M4n0TXNCVkeHUh?=
NH-12 MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHsTWM2OD1yLkGwO|Q1KM7:TR?= M{\Dd3NCVkeHUh?=
697 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnRU211UUN3ME2wMlExQDN7IN88US=> NUiwfFA{W0GQR1XS
KE-37 MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXPcphpUUN3ME2wMlEyOzdizszN MVvTRW5ITVJ?
MOLT-4 NEXQdWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMUWxOlkh|ryP NVrvbnNYW0GQR1XS
CHP-134 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f0c2lEPTB;MD6xOlMxPiEQvF2= NVziUlFLW0GQR1XS
D-283MED NETrWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLoTWM2OD1yLkG3Olg3KM7:TR?= NUDURnpZW0GQR1XS
LU-135 M3zPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTo[JZKSzVyPUCuNVg2PTJizszN NYOxfG1lW0GQR1XS
LU-134-A NIj3PXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3GTWM2OD1yLkG4OlcyKM7:TR?= MWHTRW5ITVJ?
EM-2 NEfHOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TrdWlEPTB;MD6xPVkyQCEQvF2= MWHTRW5ITVJ?
LU-139 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMkC0PVgh|ryP MoXJV2FPT0WU
ALL-PO NXjCc4dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPqOmNMUUN3ME2wMlIyQTh6IN88US=> M3jnNnNCVkeHUh?=
NB12 NXziWHpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37CO2lEPTB;MD6yN|EyPSEQvF2= NWDPSmlxW0GQR1XS
KP-N-YN MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwMkO1O|Mh|ryP M3fDXXNCVkeHUh?=
BEN M2rGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMkO5Olgh|ryP NETqdpBUSU6JRWK=
HCC1569 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[xTWM2OD1yLkK1NVA3KM7:TR?= MV3TRW5ITVJ?
HuO9 M1zlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;hfnl[UUN3ME2wMlI3PzF3IN88US=> NVH4bGROW0GQR1XS
WM-115 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMke3N|gh|ryP NWHrcIhJW0GQR1XS
CCRF-CEM M2flVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrjcYw{UUN3ME2wMlM{PTJ7IN88US=> MYLTRW5ITVJ?
IST-SL1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j0V2lEPTB;MD6zOVM1OyEQvF2= NVTjdldMW0GQR1XS
BE-13 M{X3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljHTWM2OD1yLkO2OFU6KM7:TR?= NWDwOXFuW0GQR1XS
COR-L88 NV\Lc|c1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H5ZWlEPTB;MD6zOlU1KM7:TR?= NGW4O3ZUSU6JRWK=
DOHH-2 Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7JOFVKSzVyPUCuOFExOjNizszN NIruUYNUSU6JRWK=
A704 NYTJNFZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwNEK2O{DPxE1? NGTJR2pUSU6JRWK=
KNS-81-FD MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLRVpZKSzVyPUCuOFQxOTdizszN NGHNO|dUSU6JRWK=
RPMI-8226 NXLjWXBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwNEW2OVIh|ryP M1Sye3NCVkeHUh?=
TGBC24TKB Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWiy[nhGUUN3ME2wMlQ2Pzd6IN88US=> NEHPWHRUSU6JRWK=
NCI-H1304 MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjibXpKSzVyPUCuOFYyPTdizszN MlfhV2FPT0WU
MOLT-13 NGXtcHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlqzTWM2OD1yLkS2OlE{KM7:TR?= MlGzV2FPT0WU
EW-22 NX36W|FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[4WGlrUUN3ME2wMlQ3PjdzIN88US=> Mn;jV2FPT0WU
MS-1 M1L0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwNE[5N|Mh|ryP NXz6VGpKW0GQR1XS
RMG-I MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwNEm0OlQh|ryP M{HkcXNCVkeHUh?=
NTERA-S-cl-D1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwNUCwNVkh|ryP NWDkfWtnW0GQR1XS
NCI-H1048 NUPHV5BmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwNUC5OVMh|ryP NFvtPVZUSU6JRWK=
SW1417 MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LSdGlEPTB;MD61OVQ{QCEQvF2= M{H2dnNCVkeHUh?=
DB NYPLTlc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDYcI5DUUN3ME2wMlU4ODhizszN NUDQV4YxW0GQR1XS
MEG-01 MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljNTWM2OD1yLkW4N|Ih|ryP MnTzV2FPT0WU
EW-13 M1jzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXXTYxYUUN3ME2wMlU5OzRzIN88US=> MlzWV2FPT0WU
LAMA-84 MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4SzdGlEPTB;MD61PVIxPyEQvF2= MmfTV2FPT0WU
J-RT3-T3-5 MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;VTWM2OD1yLk[wPFA5KM7:TR?= NF7weXNUSU6JRWK=
MOLT-16 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7OTWM2OD1yLk[1NlY1KM7:TR?= MkjSV2FPT0WU
DU-4475 NGHlUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\ZTWM2OD1yLk[1OFI4KM7:TR?= NHvZVlRUSU6JRWK=
HAL-01 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3WfGRlUUN3ME2wMlczPTR7IN88US=> NXXjOZloW0GQR1XS
RD M3jsdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\x[2lEPTB;MD63OVg6QSEQvF2= NU\P[4tiW0GQR1XS
OAW-28 MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPxUYxKSzVyPUCuO|g{PyEQvF2= NXXJc3dHW0GQR1XS
HCC38 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;IOmZKSzVyPUCuPFAyQSEQvF2= NFzobXdUSU6JRWK=
NMC-G1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHzTWM2OD1yLkixNVIyKM7:TR?= MnrkV2FPT0WU
EW-16 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwOEGzNlgh|ryP MXnTRW5ITVJ?
DU-145 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD5bHFTUUN3ME2wMlg6QTJ|IN88US=> M3rYXXNCVkeHUh?=
HPAF-II NYK3VY11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGftZVlKSzVyPUCuPVI3OjhizszN NFnzWXJUSU6JRWK=
A427 NXG0b|JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\lOZloUUN3ME2wMlk{ODJ{IN88US=> NEnLWolUSU6JRWK=
PA-1 Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwOUW2OFIh|ryP Moi3V2FPT0WU
OAW-42 M2fCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nSXGlEPTB;MD65OlE1PiEQvF2= NEezPGRUSU6JRWK=
L-428 NVXpVYNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzHTWM2OD1zLkCxNlUh|ryP NXW3R2RVW0GQR1XS
COLO-824 M2j5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPuZ41KSzVyPUGuNFE4ODhizszN NVyw[VZXW0GQR1XS
P30-OHK NXzURY1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fWO2lEPTB;MT6wOFY5QCEQvF2= MXzTRW5ITVJ?
NCI-H2170 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwME[yN{DPxE1? MnvhV2FPT0WU
HCC2998 M4n6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHZUI9KSzVyPUGuNFcyOzVizszN MVTTRW5ITVJ?
NB14 NHHReFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT5O296UUN3ME2xMlE{PzR6IN88US=> NUSwdmw6W0GQR1XS
TGBC1TKB Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV2zR5NCUUN3ME2xMlE1OTV{IN88US=> NYL1eoZxW0GQR1XS
KP-N-YS NXzLTYNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFwMU[yN|Yh|ryP NHLtZZlUSU6JRWK=
CAL-120 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTzZYNTUUN3ME2xMlE3PDJ7IN88US=> NVqwWHFEW0GQR1XS
SBC-1 M2fJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFwMUmwOVMh|ryP M1vG[XNCVkeHUh?=
C32 M1zkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrhOnVKSzVyPUGuNVkxQDhizszN MWXTRW5ITVJ?
HCC2157 NY\NWXdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHBdVlKSzVyPUGuNVk1QTRizszN NUXmXnVCW0GQR1XS
COLO-792 M2HLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTFwMkCwO|Eh|ryP M4m0c3NCVkeHUh?=
ES7 NFjTNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3OxRWlEPTB;MT6yO|k2OSEQvF2= M2i5RnNCVkeHUh?=
HEL M{TFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HRS2lEPTB;MT6zNVAzQSEQvF2= MVfTRW5ITVJ?
ES4 NXG1fph7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDnR41KSzVyPUGuN|Q6QThizszN NWT0cFZvW0GQR1XS
NCI-SNU-1 NVHwNIVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;jOI9KSzVyPUGuN|Y2PTVizszN M3P5N3NCVkeHUh?=
MDA-MB-415 M2Hs[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7yXIRoUUN3ME2xMlM5QDVizszN NXnUXZJlW0GQR1XS
NCI-H2342 M3uxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGi4WW9KSzVyPUGuOFAzPjlizszN M4K3bXNCVkeHUh?=
NB69 NUTaZo5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTnTWM2OD1zLkS2NlcyKM7:TR?= NXvJeFFbW0GQR1XS
D-247MG NE\GOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LMbGlEPTB;MT61NVEzOiEQvF2= MWPTRW5ITVJ?
SCC-4 NH22PXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q5fGlEPTB;MT61PVg5PyEQvF2= M3K3bXNCVkeHUh?=
HuH-7 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnHTWM2OD1zLk[3Nlk{KM7:TR?= MULTRW5ITVJ?
A388 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFwNki3NlQh|ryP MlviV2FPT0WU
Calu-3 MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFwN{C2PVch|ryP NYjncmpyW0GQR1XS
NCI-H1648 NELyXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\6UGo4UUN3ME2xMlcyPDF6IN88US=> NF\BOmtUSU6JRWK=
NCI-H2052 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\TNGhOUUN3ME2xMlczOjBzIN88US=> NFfrcFVUSU6JRWK=
Ramos-2G6-4C10 NUTGNWs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHribm9KSzVyPUGuO|M3PTZizszN Mnr1V2FPT0WU
DEL M3j4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXPS|hKSzVyPUGuO|Q3QTJizszN MkfSV2FPT0WU
SNU-423 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrOR2xTUUN3ME2xMlc5OTV5IN88US=> M{XOS3NCVkeHUh?=
COR-L23 NFPKXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnKb2lKSzVyPUGuO|k5PzRizszN NYPNUFdsW0GQR1XS
OMC-1 NXHqeHlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fZWmlEPTB;MT64OlAyPiEQvF2= NYfMb3lnW0GQR1XS
EW-11 MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:2TWM2OD1zLkm1OlU4KM7:TR?= MnzBV2FPT0WU
HSC-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO4N2ZqUUN3ME2xMlk3OzZ3IN88US=> MUXTRW5ITVJ?
MLMA NHGwb2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTFwOU[2O|ch|ryP NEOyO4ZUSU6JRWK=
RCM-1 NEftfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\aeGNvUUN3ME2yMlAxOzl7IN88US=> MnnrV2FPT0WU
MFE-280 M{DmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzQPFR[UUN3ME2yMlAzQDR6IN88US=> NGOwdVNUSU6JRWK=
ES8 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfHenBMUUN3ME2yMlI2PDdzIN88US=> MoXiV2FPT0WU
TE-11 NY\GOVFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvkTWM2OD1{LkK5OFc{KM7:TR?= MVXTRW5ITVJ?
HuO-3N1 Mkn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLJboh6UUN3ME2yMlQ5PzhizszN NFq1bVZUSU6JRWK=
MHH-NB-11 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jUXmlEPTB;Mj61NVE2QCEQvF2= MYfTRW5ITVJ?
TGBC11TKB MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\ITWM2OD1{LkW3OlgyKM7:TR?= MVLTRW5ITVJ?
HOP-92 M3XUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7UTYMxUUN3ME2yMlU5PzR|IN88US=> M3jObXNCVkeHUh?=
IGR-1 NUW4cphuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfN[Y8zUUN3ME2yMlYzODN3IN88US=> NV7lSol1W0GQR1XS
GOTO NGLRdYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDT[GxbUUN3ME2yMlY2Ozd5IN88US=> M2CxNXNCVkeHUh?=
NCI-H1650 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv4fYZKUUN3ME2yMlczOjF3IN88US=> MkWzV2FPT0WU
NCI-H1581 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJwN{m2PFEh|ryP NV7sdmVxW0GQR1XS
NCI-H2405 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f3NGlEPTB;Mj64Nlc5OiEQvF2= NU\xNm9oW0GQR1XS
U-118-MG MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHuUnVbUUN3ME2yMlk3PDlzIN88US=> MWnTRW5ITVJ?
DoTc2-4510 Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTJeHBKSzVyPUOuNFE1OTdizszN NVrNOoxHW0GQR1XS
NCI-H596 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe1eWpQUUN3ME2zMlA1QTl5IN88US=> NHnmemhUSU6JRWK=
MPP-89 M1PJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NImwVpdKSzVyPUOuNFU3PjZizszN MnvaV2FPT0WU
GCIY MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTifo9mUUN3ME2zMlIxPDlzIN88US=> MVXTRW5ITVJ?
SW626 MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTNwMkS1OFMh|ryP MonRV2FPT0WU
OCI-AML2 Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTNwM{GyO|Ih|ryP MlzqV2FPT0WU
NBsusSR NHP3RnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3xT206UUN3ME2zMlM1QTN6IN88US=> NX[w[402W0GQR1XS
AN3-CA NGXnOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvaTWM2OD1|LkS0NlM5KM7:TR?= MWrTRW5ITVJ?
EFM-19 M1e4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfzTWM2OD1|LkS4N|M6KM7:TR?= NIjJeoxUSU6JRWK=
RVH-421 MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLKTWM2OD1|LkW2PFc4KM7:TR?= MnjBV2FPT0WU
5637 MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jPfGlEPTB;Mz62NVExOyEQvF2= MU\TRW5ITVJ?
PANC-08-13 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXiwdZRWUUN3ME2zMlY{PDd{IN88US=> M3TDWnNCVkeHUh?=
H9 NFvvV5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;BW3dIUUN3ME2zMlY4OTR2IN88US=> MYnTRW5ITVJ?
KARPAS-299 NH61W4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X2SWlEPTB;Mz62O|M3OSEQvF2= M4\YUnNCVkeHUh?=
TE-5 NGLmR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTNwN{C3NFkh|ryP M3HYVHNCVkeHUh?=
NOS-1 M{W4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;TcZIzUUN3ME2zMlc6QDN2IN88US=> NHrsWlRUSU6JRWK=
HH MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7Ec3FXUUN3ME2zMlg{QDZ6IN88US=> NV20[3lQW0GQR1XS
769-P Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnMTWM2OD1|Lki5OVEh|ryP MVPTRW5ITVJ?
CHP-212 M{LsPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3CTWM2OD1|LkmyOVQ6KM7:TR?= MVvTRW5ITVJ?
NCI-H82 NYC0XVd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PFR2lEPTB;Mz65OVk{PiEQvF2= MkfOV2FPT0WU
Mo-T MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PYUmlEPTB;ND6wOFMyOiEQvF2= MYrTRW5ITVJ?
BB65-RCC NXrRZYRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHTTWM2OD12LkC0N|k6KM7:TR?= NVTzUGVnW0GQR1XS
SW1990 M{XPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL4TnNKSzVyPUSuNFU6ODhizszN MkmzV2FPT0WU
LK-2 MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFqxPVNKSzVyPUSuNVEzQTNizszN M3rFPXNCVkeHUh?=
ES5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPHOnAzUUN3ME20MlE{QTh3IN88US=> MYPTRW5ITVJ?
JVM-3 NVHaZoRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf0OWZKSzVyPUSuNVgzOjJizszN MYPTRW5ITVJ?
RPMI-7951 M4DWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP0R5dKSzVyPUSuNlI1OTNizszN NUPTZW5rW0GQR1XS
Calu-6 NUTMO3hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1e0[WlEPTB;ND6yO|g5OSEQvF2= NXHwRlZJW0GQR1XS
LC-2-ad NX3lZWR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnOfldjUUN3ME20MlI6PTZ6IN88US=> NGjHTIFUSU6JRWK=
SW954 M3n2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTRwMkm2OkDPxE1? MmDCV2FPT0WU
H-EMC-SS NHLXVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M320S2lEPTB;ND6zNVg{OSEQvF2= NWjrc|ZHW0GQR1XS
ES3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLlenFJUUN3ME20MlM2PDRzIN88US=> M2TaU3NCVkeHUh?=
no-11 M4LwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:0TWM2OD12LkO1OVU1KM7:TR?= MoPzV2FPT0WU
LAN-6 NW\jVGJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTRwNEWxPFkh|ryP M{n6XXNCVkeHUh?=
FTC-133 NXvIWXlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LWNGlEPTB;ND61N|k2KM7:TR?= MnnOV2FPT0WU
8505C NGrYWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PvcGlEPTB;ND61OFI{KM7:TR?= M{LzN3NCVkeHUh?=
SW620 NGn3c|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvWb2lKSzVyPUSuOVcxPTdizszN M4Gw[HNCVkeHUh?=
BCPAP NWHPUHFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTITVRKSzVyPUSuOlM1QDFizszN MnjtV2FPT0WU
SK-LU-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTRwNk[wPFkh|ryP NF7STmxUSU6JRWK=
NCI-H1623 M1XIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\sR2lEPTB;ND63NFIzQCEQvF2= MmrKV2FPT0WU
C2BBe1 Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\2bpdTUUN3ME20Mlc1ODB6IN88US=> M3XmUnNCVkeHUh?=
GP5d NEnvSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTRwN{izPFgh|ryP NIPTXZRUSU6JRWK=
NB6 NX;h[4ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTRwOE[yNFQh|ryP MX;TRW5ITVJ?
MDA-MB-157 MnnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13o[2lEPTB;ND64PFc3KM7:TR?= M3zsTXNCVkeHUh?=
UMC-11 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTRwOEi5OlQh|ryP NGrKUIhUSU6JRWK=
HCC1419 NYrNR2NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DEU2lEPTB;ND65NFA3OyEQvF2= MkjaV2FPT0WU
NCI-H2029 M1eyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\wOWlEPTB;ND65OFE5PSEQvF2= MmTrV2FPT0WU
LXF-289 NUm0TWRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;0V|ZKSzVyPUWuNFM4OTlizszN M{P1OHNCVkeHUh?=
KINGS-1 MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LIWmlEPTB;NT6wO|c1PCEQvF2= NHvV[41USU6JRWK=
HD-MY-Z MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfRTWM2OD13LkKzPVY6KM7:TR?= NHXCTHRUSU6JRWK=
ESS-1 MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XXUGlEPTB;NT6yOVU6PyEQvF2= M3vjWXNCVkeHUh?=
GI-1 NFqxS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTYTWM2OD13LkK3PVI3KM7:TR?= MmDHV2FPT0WU
RPMI-2650 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3DO2dyUUN3ME21MlM3OTZizszN NUnZcZV3W0GQR1XS
IA-LM Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jSRWlEPTB;NT6zPVg4OSEQvF2= M4rodXNCVkeHUh?=
KP-4 MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTVwNE[zN|Qh|ryP NEOyRW5USU6JRWK=
G-402 NVPFbYx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\GOmlEPTB;NT61NVg3PSEQvF2= NGLKVm9USU6JRWK=
OS-RC-2 MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDFTWM2OD13LkWyOlA1KM7:TR?= MYXTRW5ITVJ?
NCI-H1155 M{Pxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjZ[JRIUUN3ME21MlU1QTV3IN88US=> NXrzboVpW0GQR1XS
OE19 NIXqR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTVwNki2NlQh|ryP NHPsUItUSU6JRWK=
U-2-OS M{DpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXQTWM2OD13Lki5NFE{KM7:TR?= MWXTRW5ITVJ?
SCC-15 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;DRmlEPTB;NT65N|Y3OiEQvF2= MWXTRW5ITVJ?
NCI-H630 M3PDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPWTWM2OD13Lkm5OFA1KM7:TR?= NEDLZZpUSU6JRWK=
PFSK-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4riUmlEPTB;Nj6wOVI2QSEQvF2= M2Xzd3NCVkeHUh?=
NCI-H1770 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTZwMkC4O|Qh|ryP M2TWbXNCVkeHUh?=
SK-MEL-3 M2fDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHjTWM2OD14LkSyPVE2KM7:TR?= MlrNV2FPT0WU
LB1047-RCC NEnjSFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjVTWM2OD14LkS3OlI2KM7:TR?= NVXvSmg3W0GQR1XS
NCI-H446 M3;CWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTZwNkK5NlUh|ryP NGLSSZVUSU6JRWK=
SW780 MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTZwN{CxPFUh|ryP NYTEZ4RDW0GQR1XS
NEC8 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PDTGlEPTB;Nj63OlY{KM7:TR?= MWDTRW5ITVJ?
NOMO-1 MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTZwN{ixNVEh|ryP M4\GNnNCVkeHUh?=
COLO-668 MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\1PWlEPTB;Nj64OFM5PyEQvF2= MmnrV2FPT0WU
MC116 M17jSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj2TWM2OD14LkmzPFk4KM7:TR?= NF\ve|ZUSU6JRWK=
HCC1937 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn1TWM2OD14Lkm5NlUyKM7:TR?= M4Hqe3NCVkeHUh?=
NCI-N87 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPKTWM2OD15LkG5Nlk{KM7:TR?= MlfEV2FPT0WU
COLO-320-HSR MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTdwMkK3N|gh|ryP M{LCOnNCVkeHUh?=
HCC1806 NFXWU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIKwUHFKSzVyPUeuNlYxPDRizszN NWD0WIc3W0GQR1XS
OVCAR-3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnJXZlKSzVyPUeuN|MxOzhizszN MWHTRW5ITVJ?
NUGC-3 NF;TfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\6ZmlEPTB;Nz6zPVY6PCEQvF2= NVW0dVRIW0GQR1XS
SW1783 M2nlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP1WHJiUUN3ME23MlQ{OTd3IN88US=> NIXEcWpUSU6JRWK=
GCT M1rST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLDV5pKSzVyPUeuOVY6ODZizszN M{PoenNCVkeHUh?=
NCI-H2126 Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3yeVhKSzVyPUeuO|M3OjVizszN Mmf1V2FPT0WU
MEL-HO NU\GTGZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\pcoN[UUN3ME23Mlc4ODV2IN88US=> NUXsV|VbW0GQR1XS
CAPAN-1 M1X6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPadoRKSzVyPUeuO|c{PTdizszN MnrvV2FPT0WU
SW756 NGTiOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[xWHM2UUN3ME23Mlc5OzN|IN88US=> NYDFTGNbW0GQR1XS
SKG-IIIa M2XUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTdwOEG4PVIh|ryP MkjMV2FPT0WU
HCE-T MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK4d5FKSzVyPUeuPFc4QDNizszN NFfvRVZUSU6JRWK=
Ca-Ski NFS3TXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGxPZdUUUN3ME23Mlk6Ozh|IN88US=> NWrnNm5GW0GQR1XS
COLO-684 NVP2d|BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\TN4FKSzVyPUiuNFE5OThizszN M16yPHNCVkeHUh?=
KYSE-70 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRThwMEe3Nlkh|ryP MWDTRW5ITVJ?
TI-73 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7DTWxKSzVyPUiuNlU5PTFizszN MlmyV2FPT0WU
BT-20 NX[3PGJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LYPGlEPTB;OD6yOlA2OiEQvF2= NEjZbFVUSU6JRWK=
MHH-ES-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRThwNUG4N|Qh|ryP MkfjV2FPT0WU
TE-12 MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTCTWM2OD16LkW5PVMyKM7:TR?= MmXLV2FPT0WU
YH-13 NVLx[|VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRThwNkGwNFgh|ryP MUDTRW5ITVJ?
SF126 NHHZTVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXwepdVUUN3ME24Mlg{QDZ3IN88US=> M{HIT3NCVkeHUh?=
J82 M4TiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRThwOUCwN|gh|ryP MofvV2FPT0WU
RCC10RGB MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz3TWM2OD16Lkm5OVYyKM7:TR?= MlLrV2FPT0WU
SK-UT-1 NYT3RZN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofuTWM2OD17LkC0PVQ2KM7:TR?= M4TaO3NCVkeHUh?=
LB2241-RCC MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULuZllvUUN3ME25MlE6OTN5IN88US=> NUTae5oyW0GQR1XS
LB996-RCC NGWyeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTlwMUm4PUDPxE1? M1LWPXNCVkeHUh?=
EPLC-272H NEjjW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q3[WlEPTB;OT6zO|Y2PyEQvF2= NETEe3RUSU6JRWK=
CTV-1 M3jhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;6VVhKSzVyPUmuOVY2OzJizszN NHjuV45USU6JRWK=
HSC-2 M1y1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPLTWM2OD17LkW3OVUh|ryP M1O0UXNCVkeHUh?=
SK-MEL-28 MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHi4PIpKSzVyPUmuOlE5QTNizszN MYnTRW5ITVJ?
MMAC-SF Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\RcmlEPTB;OT62PFc2KM7:TR?= MkXjV2FPT0WU
CP50-MEL-B M2faVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTlwN{W3PFIh|ryP NHThZodUSU6JRWK=
HT-1080 MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LKdmlEPTB;OT63O|c{QSEQvF2= NVjtc2RPW0GQR1XS
HEC-1 NVXNc4FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4qz[mlEPTB;MUCuN|M2OiEQvF2= MX;TRW5ITVJ?
AGS NYjmZZA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nnPWlEPTB;MUCuN|c1KM7:TR?= NVvwPXNbW0GQR1XS
GAMG MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrhXoRFUUN3ME2xNE42OTZ{IN88US=> MUnTRW5ITVJ?
SW48 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXGyOXN3UUN3ME2xNE42OTh7IN88US=> NXrkVWQxW0GQR1XS
U031 NWTaOlk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG3TWM2OD1zMD61PVA5KM7:TR?= MXvTRW5ITVJ?
OVCAR-5 Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HmeWlEPTB;MUCuOlQzQSEQvF2= NWP0bpNIW0GQR1XS
SF295 NWrRc4RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFyLk[3NFQh|ryP M{jPZ3NCVkeHUh?=
BHT-101 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnexTWM2OD1zMD63NVc4KM7:TR?= NITLeIRUSU6JRWK=
VMRC-RCZ MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PQcmlEPTB;MUGuN|IxOSEQvF2= MmfSV2FPT0WU
ACHN M2To[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXWWGV3UUN3ME2xNU41OjFzIN88US=> NGm4clhUSU6JRWK=
NCI-H526 M1Xvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7pZVBNUUN3ME2xNU42ODR|IN88US=> MXPTRW5ITVJ?
MN-60 MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HYOWlEPTB;MUGuOVM6KM7:TR?= MmTOV2FPT0WU
NCI-H2291 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnqTZJFUUN3ME2xNU42PDZ4IN88US=> M3vTUHNCVkeHUh?=
SCC-25 M1zscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe0[5RDUUN3ME2xNU44PTV4IN88US=> MmrGV2FPT0WU
SK-MEL-2 M3PvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjXTmxKSzVyPUGxMlc3OzdizszN MUHTRW5ITVJ?
SN12C MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi4e|VZUUN3ME2xNU46OzV3IN88US=> NXjiZXFbW0GQR1XS
NCI-H69 MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF{LkSyN|Qh|ryP NXHVeWExW0GQR1XS
ME-180 M1q5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLmfZNWUUN3ME2xNk44ODV2IN88US=> NEDPdolUSU6JRWK=
MC-IXC M1XwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnNdHNKSzVyPUGyMlc2OThizszN NFG2UGlUSU6JRWK=
NCI-H2347 NEPpcm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jJXWlEPTB;MUKuO|YyPCEQvF2= NULZR3ZFW0GQR1XS
M059J NHjtUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLDbGdLUUN3ME2xNk44PzJ5IN88US=> NXjGV4hIW0GQR1XS
A2058 MkTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXzTWM2OD1zMj64OlgyKM7:TR?= MYfTRW5ITVJ?
VA-ES-BJ MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LzSWlEPTB;MUKuPFc5PSEQvF2= Mly2V2FPT0WU
Ca9-22 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTqboZnUUN3ME2xNk46PDVzIN88US=> M322OHNCVkeHUh?=
KNS-42 M1TKdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC4TWM2OD1zMj65PVg1KM7:TR?= NVO3TJFLW0GQR1XS
LoVo M3XFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHvd|JCUUN3ME2xN{4zOzF|IN88US=> MWDTRW5ITVJ?
AM-38 NGW3[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHOTWM2OD1zMz6yOVY3KM7:TR?= MoXqV2FPT0WU
NB5 NXrKVGJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF|LkO3OVIh|ryP MYnTRW5ITVJ?
L-363 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzYeHRwUUN3ME2xN{41ODN|IN88US=> MUnTRW5ITVJ?
SK-MEL-30 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnlVWs6UUN3ME2xOE4xPjR3IN88US=> NFXlPVVUSU6JRWK=
NCI-H1563 M1\zUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\qWGhKSzVyPUG0MlYxOzlizszN M3THPXNCVkeHUh?=
NCI-H2228 NVLxWINtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X3ZWlEPTB;MUSuOlA4PyEQvF2= M2rYWnNCVkeHUh?=
MFM-223 M1nte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnuTWM2OD1zNT6xPFE{KM7:TR?= Mlz3V2FPT0WU
LB831-BLC M4\LbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LD[GlEPTB;MUWuNlc3PyEQvF2= M3HKOHNCVkeHUh?=
SW872 M3vQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\TfmhKSzVyPUG1MlMxQDZizszN M3T6OHNCVkeHUh?=
NCI-H522 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF3LkOzNFYh|ryP M16xUnNCVkeHUh?=
EW-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly5TWM2OD1zNT61OFYzKM7:TR?= MkD2V2FPT0WU
HN MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXuZZVKSzVyPUG1MlU6PDJizszN MYHTRW5ITVJ?
SW837 M1LlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHZcIkzUUN3ME2xOU44QDR5IN88US=> NH:wdXVUSU6JRWK=
SCC-9 NFPF[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonMTWM2OD1zNT64NVE1KM7:TR?= M1LjPHNCVkeHUh?=
MKN7 M2rCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7SboFKUUN3ME2xOU46PzN{IN88US=> M1nyfHNCVkeHUh?=
KYSE-410 M3XBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4n3eGlEPTB;MU[uOVkyKM7:TR?= NGC1T3dUSU6JRWK=
SK-N-DZ MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXkTWM2OD1zNj62NVE3KM7:TR?= M{\JOnNCVkeHUh?=
COR-L105 NHzqfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfOfFFKSzVyPUG2MlY2OjhizszN M{PyfHNCVkeHUh?=
LB2518-MEL MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37vTmlEPTB;MU[uPFM5QSEQvF2= NYrOZlB{W0GQR1XS
OVCAR-4 MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PESWlEPTB;MU[uPFg3OiEQvF2= NEWwcZRUSU6JRWK=
TK10 NHTBXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fhTGlEPTB;MU[uPVQ4OyEQvF2= MXLTRW5ITVJ?
KNS-62 NHjBS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHLSYlKSzVyPUG2Mlk4PzdizszN M3;peHNCVkeHUh?=
RPMI-8866 NETzR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYKyeW1OUUN3ME2xO{4yPzN{IN88US=> M4THcnNCVkeHUh?=
HuP-T4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPvdVNHUUN3ME2xO{4zPDl3IN88US=> MlKwV2FPT0WU
CGTH-W-1 M3;vVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHWyfW5KSzVyPUG3MlUzOTlizszN NVTNVlVFW0GQR1XS
T-24 NHXXOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33ibGlEPTB;MUeuOVM1PyEQvF2= NInEW5BUSU6JRWK=
HT-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonVTWM2OD1zNz61PVE1KM7:TR?= NUH0XoZNW0GQR1XS
KS-1 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLTTWM2OD1zNz62O|Mh|ryP MkP2V2FPT0WU
NCI-H1792 NXvacG11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n4TmlEPTB;MUeuO|k5KM7:TR?= NYezeGR{W0GQR1XS
ABC-1 M3rFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXETXNKSzVyPUG3MlgyPDFizszN NGDiboZUSU6JRWK=
BPH-1 NWSzPGZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz2VYFQUUN3ME2xPE4yPjh3IN88US=> NI\V[XpUSU6JRWK=
A431 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTF6LkSxNlch|ryP NXLLdIVVW0GQR1XS
T98G NEm4fJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnFcI5zUUN3ME2xPE42OTV5IN88US=> M4Xzb3NCVkeHUh?=
BHY MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF6Lki2PUDPxE1? NVXLcY5uW0GQR1XS
Capan-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTF6LkmwO|gh|ryP MY\TRW5ITVJ?
MDA-MB-175-VII NWfxT4wzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETvOm5KSzVyPUG4MlkzODlizszN MY\TRW5ITVJ?
CAL-27 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XxfWlEPTB;MUmuNFQ5PyEQvF2= Ml75V2FPT0WU
AsPC-1 NFvZPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\zfGFKSzVyPUG5Mlg3PTdizszN NH3rdYlUSU6JRWK=
KU812 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvSTWM2OD1zOT65OVc{KM7:TR?= NV3QPXZIW0GQR1XS
NCI-H441 NV\vdFBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\uTWM2OD1{MD6wNFEh|ryP NVnFTmdsW0GQR1XS
Mewo NYjGUWNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfpNGV5UUN3ME2yNE4yOjh6IN88US=> M{S2O3NCVkeHUh?=
SK-MEL-24 NEKxTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJyLkG0O|ch|ryP Mm\GV2FPT0WU
NCI-H727 NFrOfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfGfmRKSzVyPUKwMlI4ODRizszN MW\TRW5ITVJ?
EKVX M2\rdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjScWdKSzVyPUKwMlYxPiEQvF2= M{\rVHNCVkeHUh?=
RT-112 NIPYOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJyLk[xNlIh|ryP M2fKdnNCVkeHUh?=
CAMA-1 M3PldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;hZmtyUUN3ME2yNE46QDB|IN88US=> NWez[3VpW0GQR1XS
SW900 M4K1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\FUVA2UUN3ME2yNU4xOTR7IN88US=> NVqyUmdjW0GQR1XS
NCI-H23 NUXyV21UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJzLkGyO|ch|ryP NV;FXo51W0GQR1XS
SK-PN-DW NHjlPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJzLkG2OFkh|ryP M3rGSnNCVkeHUh?=
BB30-HNC NFfGeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DpVmlEPTB;MkGuNlc1PSEQvF2= MWrTRW5ITVJ?
VM-CUB-1 M4fjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf5XJNKSzVyPUKxMlM2OzZizszN NWnIb20zW0GQR1XS
IST-MEL1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYi3UoRxUUN3ME2yNU4{Pjl{IN88US=> NGPTTWpUSU6JRWK=
CTB-1 NFrLdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3tcIlKSzVyPUKxMlQ4PTVizszN MXzTRW5ITVJ?
LCLC-103H MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XM[2lEPTB;MkKuNVU5OiEQvF2= M3mybXNCVkeHUh?=
PANC-03-27 M2LpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHpO2xLUUN3ME2yNk42OTZ7IN88US=> M1X1XXNCVkeHUh?=
HTC-C3 NFTGPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW4TWM2OD1{Mj61OVU2KM7:TR?= M{P0W3NCVkeHUh?=
TE-8 M{jYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLETWM2OD1{Mz6yOVY2KM7:TR?= MXLTRW5ITVJ?
NCI-H292 NV7oSYFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoizTWM2OD1{NT6zOVM3KM7:TR?= MlrjV2FPT0WU
COLO-680N MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[w[pRKSzVyPUK1MlY{OjlizszN MkjUV2FPT0WU
KYSE-520 NUHvO|J4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJ3Lk[0OEDPxE1? NWr5XIoxW0GQR1XS
NB10 M3zDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTSTWM2OD1{Nj6zNVE4KM7:TR?= NIXlXGdUSU6JRWK=
NCI-H661 NYq2Oo8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfJU|lKSzVyPUK2MlQ4OTNizszN MX;TRW5ITVJ?
GMS-10 NGLqcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX1TWM2OD1{Nj64OlM5KM7:TR?= MVPTRW5ITVJ?
NCI-H2122 M17YW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXyTWM2OD1{Nj65PVk5KM7:TR?= MXnTRW5ITVJ?
OVCAR-8 NYPNVIpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ5LkC2N|gh|ryP M2Pld3NCVkeHUh?=
DJM-1 M3XFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O4TmlEPTB;MkeuNVQ2PCEQvF2= MWfTRW5ITVJ?
UACC-893 MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfTTWM2OD1{Nz65PFc5KM7:TR?= MVvTRW5ITVJ?
C8166 MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr0TWM2OD1{OD62PVM5KM7:TR?= NIK5XVVUSU6JRWK=
NCI-H1693 MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzSNHh4UUN3ME2yPE43QTd3IN88US=> MkDRV2FPT0WU
TYK-nu NUHFVlN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj0TWM2OD1|MD6wN|Q2KM7:TR?= MnPtV2FPT0WU
SW1710 NWDyb5ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLtXoRKSzVyPUOwMlEzPiEQvF2= M3ew[nNCVkeHUh?=
A375 MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzUTWM2OD1|MD6zNlQ{KM7:TR?= MUfTRW5ITVJ?
HMV-II Mom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTNzLkO1PVIh|ryP NWnjbmYyW0GQR1XS
NCI-H2087 M4jZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjFPJRKSzVyPUOxMlY{PTJizszN MmmxV2FPT0WU
CAL-54 NHPpZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnmTWM2OD1|MT63NlQyKM7:TR?= NXXF[|Z{W0GQR1XS
HCC70 Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTN{LkGzPFch|ryP M{L2cnNCVkeHUh?=
ES1 NGfKOIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{OzVGlEPTB;M{KuN|A3OiEQvF2= NXW0cndrW0GQR1XS
NCI-H1355 NHXRb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\idY1qUUN3ME2zN{4zODRizszN MmXQV2FPT0WU
CFPAC-1 NFr1WmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jjXWlEPTB;M{OuNlM{OiEQvF2= MYrTRW5ITVJ?
MKN28 NXfjTHNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;qTWM2OD1|Mz6zPFA6KM7:TR?= NV;PO29WW0GQR1XS
HDLM-2 MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTN|Lk[5N|Eh|ryP Mmm4V2FPT0WU
PANC-10-05 MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f2TmlEPTB;M{SuNVAyPCEQvF2= NX7FTHdPW0GQR1XS
SAS M172bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXNTWM2OD1|ND60OVY2KM7:TR?= NEfLc2ZUSU6JRWK=
HCC1395 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXwdWdKSzVyPUO0MlcyQDZizszN Ml\GV2FPT0WU
8305C MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTN3Lki0NVUh|ryP MULTRW5ITVJ?
KM12 NI[yUWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m2bWlEPTB;M{[uO|U1PyEQvF2= NV3h[Hg2W0GQR1XS
SW1116 MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vwc2lEPTB;M{euOVk6OiEQvF2= MYnTRW5ITVJ?
SK-MEL-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLTeGlKSzVyPUO4MlM{QDlizszN NYnYWYp5W0GQR1XS
HCC2218 NVrnUGFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTN6Lk[1NVkh|ryP MUTTRW5ITVJ?
T84 NYHCdplyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTN6Lke0NFkh|ryP MoqxV2FPT0WU
ETK-1 NFvicmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7OeppKSzVyPUO5MlAzOiEQvF2= M2rk[HNCVkeHUh?=
COLO-800 MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTN7LkO4Olgh|ryP NFi0epVUSU6JRWK=
CAL-12T NEX3c4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDRUG9KSzVyPUO5MlUzQDFizszN NHfBUmFUSU6JRWK=
ACN MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fPRmlEPTB;NECuOFkyOSEQvF2= NGLNNVNUSU6JRWK=
SJSA-1 M3jLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTjUZZKSzVyPUSxMlE2QTZizszN NXTadItMW0GQR1XS
PSN1 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTRzLkG3OFkh|ryP NFKxN29USU6JRWK=
D-566MG M2HvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHBN5VKSzVyPUSxMlIxQDZizszN NFPOfW5USU6JRWK=
EGI-1 NGmzT|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4CzTWlEPTB;NEKuOFI5KM7:TR?= MYHTRW5ITVJ?
A204 M{DFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnznTWM2OD12Mj62N|g5KM7:TR?= M4TGSXNCVkeHUh?=
Saos-2 MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPZelhXUUN3ME20Nk45OzZ7IN88US=> NVTNVFc4W0GQR1XS
SNU-C2B M{GzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTwO5BKSzVyPUSzMlY5PzhizszN MnSxV2FPT0WU
HLE M2jJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn5TWM2OD12ND6wPFU3KM7:TR?= NF:1eJJUSU6JRWK=
SW1463 NIXyb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK4TWM2OD12ND65PVcyKM7:TR?= Mn7VV2FPT0WU
DSH1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnnbm86UUN3ME20OU4xODN|IN88US=> MVPTRW5ITVJ?
MCF7 NHnUT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP5b3NKSzVyPUS1MlUxPTFizszN Mk[zV2FPT0WU
K5 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33CU2lEPTB;NEWuPVQxPSEQvF2= MkG5V2FPT0WU
NCI-H358 MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljmTWM2OD12Nz6yNVUh|ryP NHzFenVUSU6JRWK=
NCI-H2030 M1e0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHy[Yk2UUN3ME20O{4zOzd2IN88US=> NGTPWHlUSU6JRWK=
SW948 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fKSmlEPTB;NEeuOFY1KM7:TR?= MULTRW5ITVJ?
BALL-1 NVTBfItTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\iWIFKSzVyPUS3MlYyPjhizszN NVrLZmNPW0GQR1XS
TE-9 NFPv[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTR5Lkm1PFEh|ryP MoDiV2FPT0WU
SK-N-FI NUnXSnZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTR6LkCzOVgh|ryP Mn7GV2FPT0WU
KALS-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvMe2xRUUN3ME20PE4yOjh7IN88US=> NUi3[JFPW0GQR1XS
HO-1-N-1 NES3RnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHwTWM2OD12OD63OFQ2KM7:TR?= MnXFV2FPT0WU
NCI-H2452 MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTR7LkGxOVIh|ryP M1y1bHNCVkeHUh?=
OC-314 NXnke|F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\nc2ZKSzVyPUS5MlY5OzRizszN NFSwfFlUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO+corn oil
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID